Arranta Bio Investor
Arranta Bio was formed in May 2019 with the vision to be the best-in-class microbiome CDMO, developing and manufacturing live biotherapeutic products (LBPs) for pioneers targeting diseases linked to the microbiome, using bacterial fermentation, isolation, drying and encapsulation. In October 2019, we completed an $82,000,000 funding round with sole institutional investor, Ampersand Capital, company founders and colleagues, and a strategic investment from Thermo Fisher Scientific.
Technology:
Biomarker Discovery & Validation
Industry:
BioPharma AI
Founded Date:
2019-01-01
Investor Type:
Private Equity Funds
Employee Number:
51-100
Headquarters:
Watertown,Massachusetts,United States,North America
Funding Status:
private